Amarin (NASDAQ:AMRN) is up 11% premarket on robust volume. Shares have tripled since early February. Investors appear bullish, albeit a bit early, on the interim analysis of the REDUCE-IT trial, due next year. Positive results will pave the way for a label expansion for Vascepa (icosapent ethyl).